The oral phase of Huskast 4mg pharmaceuticals 3-2 treatment of chronic bronchial asthma (28 packs x 0.5g)

Dosage form Box of 28 packs
Specifications Montelukast

Ingredient

Composition information	Content
Montelukast	4mg

Uses

indications

HISKAST drugs are indicated in the following cases:

Indications for elderly and children over 2 years of age to prevent and treat chronic bronchial asthma, including preventing both day and night asthma symptoms, treating aspirin sensitive asthma, and preventing bronchospasm due to exertion.

Reduce the symptoms of day and night of seasonal allergic and allergic allergies for adults and children 2 years of age and older.

Pharmacokic

Montelukast oral form is anti -inflammatory substance, improving parameters of asthma inflammation. Based on biochemical and pharmacological tests, Montelukast proves high affinity and selective selection with CYSLT receptor (this effect is superior to other receptors that are also important in pharmacological, such as the Prostanoid, Cholinergic or β - Adrenergic). Montelukast strongly inhibits the physiological effects of LTC. Ltd.

In Hen Hen, Montelukast inhibits cysteinyl leucotriene recipes, which shows the ability to inhibit bronchospasm due to Ltd4 inhalation. With doses of less than 5mg, the bronchospasm of Ltd. Montelukast causes bronchiectasis for 2 hours after drinking, these effects are in conjunction with bronchodilator by using the owner.

Dynamic pharmacokinetics

After drinking, Montelukast absorbs quickly and almost completely. With 10mg film tablets, CMAX reaches 3 hours TMAX. After adults drink when hungry. Born when drinking is 64%. The uses are available and CMAX. Not affected by a standard meal.

Montelukast attaches more than 9% to plasma proteins. Montelukast's purification in plasma is 45ml/minute healthy adults. After taking Montelukast, it is found that 86% of the markers are found in the feces of a total of 5 days and less than 0.2% discharged through the urine.

Before taking The oral phase of Huskast 4mg pharmaceuticals 3-2 treatment of chronic bronchial asthma (28 packs x 0.5g)

How to use

Take oral use. Can take medicine with or without food.

Dosage

Use once a day. To treat asthma, need to take medicine in the evening. With allergic rhinitis. Time to use the drug depends on the needs of each object. For patients with both asthma and allergic rhinitis, should be used a dose every day, in the evening.

Children 2 - 14 years old have asthma and/ or allergic rhinitis: 1 pack a day.

Patients continue to take the drug even though the asthma attacks have been controlled, as well as in periods of severe asthma.

Note: The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.What to do when overdose? The most common reactions are similar to Montelukast's safety properties including abdominal pain, drowsiness, thirst, headache, vomiting and excitement. It is unclear whether Montelukast can be separated through peritoneal or dialysis.

What to do when you forget a dose? However, if close to the next dose, skip the forgotten dose and take the next dose at the time as planned. Note that it should not be used double the prescribed dose.

Side Effects

When using Hishast, you may experience unwanted effects (ADR).

Common, ADR> 1/100

No report.

Uncommon, 1/1000

No report.

Rare, ADR

Digestive: Nausea, vomiting, indigestion, diarrhea.

Liver -Expiration: increase AST and ALT, cholestatic hepatitis.

musculoskeletal: joint pain, muscle pain includes muscle contraction.

Other: Increases the likelihood of bleeding, bleeding, bleeding under the skin, brushing chest and edema, convulsions

Not determined frequency:

The immune system: Hypersensitive reactions (including angioedema, itching, rash, urticaria).

Body: Abnormal dream, hallucinations, drowsiness, agitation include acts of aggression, hyperactivity, insomnia, abnormal/sensory reduction.

Instructions on how to handle ADR

Unwanted effects are usually mild and often do not need to stop the drug. Notify the doctor that the unwanted effect is encountered when using the drug.

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

contraindicated

anti -contraindications in the following cases:

Hypersensitivity to any ingredients of the drug.

Be cautious when used

has not been valid when taking Montelukast in the treatment of provincial asthma attacks. Therefore, Montelukast should not be used to treat acute asthma attacks. Patients need to be instructed to use the appropriate treatment.

When reducing the dose of corticosteroids using systemic sugar in patients using other anti-asthma drugs, including Leukotriene receptor antagonists, they will lead to in a rare number of cases: Eosin hyperpses, rashes, shortesthesia, complications of injection and/or neurological disease sometimes diagnosed as churg-strauss syndrome is EOSIN hypotension. Although the cause and effect is not identified with Leukotrien receptor antagonists, it is necessary to be cautious and closely monitor clinical when reducing the dosage of all sugar corticosteroids in patients using Montelukast.

Be cautious when used for pregnant and lactating women.

The ability to drive and operate machinery

does not affect.

Pregnancy

Precautions when used.

breastfeeding period

Precautions when using.

Medicinal interaction

can be used Montelukast with other commonly used drugs in preventive and chronic treatment of asthma and treatment of allergic rhinitis.

In medication interactive studies, Liao found that Montelukast's recommendations do not have a significant effect on the pharmacokinetics of the following drugs: Theophylline, prednisone, prednisolone, birth control pills, terfenadine, digoxin and warfarin. The area under the curve of Montelukasz is reduced by about 40% in humans with phenobarbital. In vitro studies show that Montelukast is CYP2C inhibitor.

However, data from drug interactive studies with each other clinically by Montelukast and Rosiglitazone shows that Montelukast does not inhibit CYP2C8 In Vivo. Therefore, Montelukast does not change the metabolism of drugs that are metabolized mainly through this enzyme.

Storage

In closed packaging, dry place. Avoid moisture. The temperature does not exceed 30 ° C.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.